UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of March 2024
Commission file number: 001-38041
SCISPARC LTD.
(Translation of registrant’s name into English)
20 Raul Wallenberg Street, Tower A,
Tel Aviv 6971916 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
On March 6, 2024, SciSparc
Ltd. (the “Company”) issued a press release titled “SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain
Management Technology.”
On March 7, 2024, the Company
issued a press release titled “SciSparc Granted Patent for Core Technology in Multiple Jurisdictions in Europe.”
On March 8, 2024, the Company issued a press release titled “SciSparc
Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder.”
The first two paragraphs
and the section titled “Forward-Looking Statements” in the press release attached as Exhibit 99.1, the press release
attached as Exhibit 99.2, and the first, second, and fourth paragraphs and the section titled “Forward-Looking
Statements” in the press release attached as Exhibit 99.3 to this Report of Foreign Private Issuer on Form 6-K are
incorporated by reference into the Company’s registration statements on Form F-3 (File No. 333-275305,
File No. 333-269839, File
No. 333-266047, File
No. 333-233417, File No. 333-248670,
File No. 333-255408,
and File No. 333-275305)
and on Form S-8 (File No. 333-225773)
filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the
extent not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
SciSparc Ltd. |
| |
|
|
| Date: March 8, 2024 |
By: |
/s/ Oz Adler |
| |
Name: |
Oz Adler |
| |
Title: |
Chief Executive Officer and Chief Financial Officer |
3
Exhibit 99.1
SciSparc Issued Canadian Patent for
Opioids Reduction Use in Pain Management Technology
TEL AVIV, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd.
(Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development
of therapies to treat disorders and rare diseases of the central nervous system, announced today its had been received patent approval
for its proprietary combination of opioids and n-acylethanolamines for pain treatment (the “Patent”).
The Patent has been granted by the Canadian Intellectual Property Office,
the government agency in Canada that administers intellectual property rights and legislation for patents.
According to a report by Grand View Research, the global opioid market
was valued at $22.8 billion in 2022 and is anticipated to grow at a compound annual growth rate of 1.4% from 2023 to 2030. The
increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected
to drive market growth. At the same time, opioid abuse and addiction has been a global growing epidemic for more than a decade.
“With the Canadian patent approval for our opioid reduction technology,
SciSparc continues to build on global recognition of its innovations and breakthrough technologies. We are all aware of how effective
opiates are in relieving pain, but also for their addictive influence. We believe that our technology will potentially make it possible
to improve the therapeutic effect of opiates in lower doses, thereby reducing their addictive potential. Our technology represents hope
for safer and more effective pain management strategies worldwide,” said SciSparc’s Chief Executive Officer, Oz Adler.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company
led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies
and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs
based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp seeds oil-based products on Amazon Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning
of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For
example, SciSparc is using forward-looking statements when it discusses the anticipated growth and reasons for the growth of the global
opioid market, the belief that the Company’s technology will improve the therapeutic effect of opiates in lower doses, and that
the Company’s technology represents hope for safer and more effective pain management strategies worldwide. Historical results of
scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest
identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc’s current expectations,
they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially
from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this
press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s
Annual Report on Form 20-F filed with the SEC on May 1, 2023, and in subsequent filings with the U.S. Securities and Exchange Commission.
Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements,
which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
Exhibit 99.2
SciSparc
Granted Patent for Core Technology in Multiple Jurisdictions in Europe
The Company’s most recent patent further solidifies
its position, complementing existing grants in the U.S., Japan, Australia and other key jurisdictions
TEL AVIV, Israel, March 07, 2024 (GLOBE NEWSWIRE)
-- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing
on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that the process of
granting and validation for its core-technology patent has been completed in certain European countries. This patent covers combinations
of cannabinoids and n-acylethanolamines (the “Patent”). The Patent aligns seamlessly with the Company’s proprietary technology
designed to enhance the safety of cannabinoids by using low dosages of active components while maintaining their therapeutic benefits.
The Patent was granted and validated in Austria,
Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Liechtenstein and the United
Kingdom.
This grant adds to the patent portfolio of the
Company, thereby supporting the innovation of SciSparc’s technologies.
The invention relates to compositions and methods
for potentiating therapeutic effects and/or reducing the side-effects of selected cannabinoids initially discovered in the cannabis plant.
The Patent approval was granted on account of the unique composition of cannabinoids and n-acylethanolamines and the methods for their
use in preventing and treating a variety of cannabinoid-treated conditions.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical
company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio
of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug
development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s
disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also
owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds oil-based products on the Amazon.com Marketplace.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
Exhibit 99.3
SciSparc
Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
TEL
AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty
clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today
announced that the first patient has been enrolled in the Company’s clinical trial assessing the efficacy and safety of SCI-210 for the
treatment of children with autism spectrum disorder (“ASD”) between the ages of 5 and 18.
Autism, also referred to as autism spectrum disorder, is one of the
most common developmental disabilities globally with a prevalence of approximately one in 36 children, according to estimates from the
Centers for Disease Control and Prevention’s Autism and Developmental Disabilities Monitoring (ADDM) Network and
is accompanied by an unmet need for efficient and safe treatments.
“Scientific innovation cannot forge ahead without patients that
are willing to work with the scientific community by participating in clinical trials. The enrollment of our first patient means that
we are moving towards a new frontier in the treatment of ASD,” said Oz Adler, SciSparc’s Chief Executive Officer. “We
are pleased to enroll the first patient in the trial, which will further our understanding of the potential role of SCI-210 in the treatment
of ASD symptoms.”
The Company’s goal is to sell SCI-210 first in Israel and then in other
countries, subject to obtaining the requisite regulatory approvals.
About the ASD trial:
The double-blind, randomized and placebo-controlled study will be performed
using SciSparc’s proprietary SCI-210, a combination of cannabidiol (CBD) and CannAmide™ (SciSparc’s Palmitoylethanolamide),
which is designed to alleviate ASD symptoms. SciSparc will enroll 60 subjects between the ages of 5 and 18, for 20 weeks, with the purpose
of assessing how SCI-210 therapy compares to standard CBD treatment in managing symptoms of ASD.
The trial has three primary efficacy metrics: the Aberrant Behavior
Checklist-Community (ABC-C) parent questionnaire; the Clinical Global Impressions-Improvement (CGI-I) performed by a clinician; and the
effective therapeutic dose. The trial was designed in consultation with the National Autism Research Center, the leading research center
for autism in Israel.
ASD is a condition related to brain development
that impacts how a person perceives and socializes with others, causing problems in social interaction and communication. The term “spectrum”
in autism spectrum disorder refers to the wide range of symptoms and severity.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company
led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies
and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs
based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer’s disease and
agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling
interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning
of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For
example, SciSparc is using forward-looking statements when it discusses the Company’s vision for treating ASD through clinical trials
testing the SCI-210 composition and its goal to sell SCI-210 in Israel and other countries subject to the requisite regulatory approvals.
Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research
or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc’s
current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc
could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained
or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk
Factors” in SciSparc’s Annual Report on Form 20-F filed with the SEC on May 1, 2023, and in subsequent filings with the U.S.
Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise
any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events
or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Mar 2024 to Apr 2024
SciSparc (NASDAQ:SPRC)
Historical Stock Chart
From Apr 2023 to Apr 2024
